IMUNON Announces Site Activation for IMNN-101 Phase 1 Vaccine Study
May 13, 2024 09:00 ET
|
Imunon, Inc.
Proof-of-concept study for Imunon’s first vaccine utilizing its proprietary PlaCCine platform is now open for enrollment Topline results expected this year LAWRENCEVILLE, N.J., May 13, 2024 ...
Imunon to Hold Third Quarter 2022 Financial Results and Business Update Conference Call on Monday, November 14, 2022
November 07, 2022 08:30 ET
|
Imunon, Inc.
LAWRENCEVILLE, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Imunon, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on DNA-mediated immunotherapy and next-generation vaccines,...
Corbus Pharmaceuticals Updates Data from Lenabasum Open-Label Extension Studies in Systemic Sclerosis and Dermatomyositis at 2019 ACR Annual Meeting
November 11, 2019 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Median ACR CRISS score remains 0.95 at 25 months in systemic sclerosis OLE Improvement in CDASI activity score reaches -20.9 points at 23 months in dermatomyositis OLE Favorable safety profile...
ConSynance Presents CSTI-100 Data at NASH Conference
September 27, 2018 09:00 ET
|
ConSynance Therapeutics, Inc.
Rensselaer, New York., Sept. 27, 2018 (GLOBE NEWSWIRE) -- ConSynance Therapeutics, Inc. announced today that Peter Guzzo, Ph.D., CEO, gave an oral presentation regarding the company's Phase I...